Genelux (GNLX) Enterprise Value (2022 - 2026)
Genelux (GNLX) posted quarterly Enterprise Value of -$9.3 million for Q1 2026, up 32.8% year-over-year from -$7.0 million in Q1 2025, and up 24.09% quarter-over-quarter from -$12.2 million in Q4 2025.
Genelux (GNLX) Enterprise Value (2022 - 2026) Analysis & Trends
Genelux's Enterprise Value history runs 5 years deep, the most recent figure standing at -$9.3 million for Q1 2026.
- In Q1 2026, Enterprise Value rose 32.8% year-over-year to -$9.3 million; the TTM figure through Mar 2026 stood at -$9.3 million (up 32.8% YoY), while the FY2025 annual figure was -$12.2 million, up 60.46% from the prior year.
- Enterprise Value for Q1 2026 stood at -$9.3 million, up from -$12.2 million in the prior quarter.
- The five-year high for Enterprise Value was -$397000.0 in Q4 2022, with the low at -$66.2 million in Q2 2024.
- The 5-year median for Enterprise Value is -$25.8 million (2023), against an average of -$29.2 million.
- The sharpest annual moves came in 2023 and 2025: Enterprise Value sank 5365.24% in 2023, then surged 66.52% in 2025.
- Genelux's Enterprise Value stood at -$397000.0 in 2022, then tumbled by 5365.24% to -$21.7 million in 2023, then plunged by 42.39% to -$30.9 million in 2024, then soared by 60.46% to -$12.2 million in 2025, then advanced by 24.09% to -$9.3 million in 2026.
- Business Quant data shows GNLX's Enterprise Value at -$9.3 million in Q1 2026, -$12.2 million in Q4 2025, and -$20.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.05 Bn | 131.20 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 85.99 Bn | 78.00 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 65.49 Bn | 60.31 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 56.79 Bn | 51.65 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 42.14 Bn | 37.05 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.27 Bn | 992.69 Mn | -3.31 Bn |
| 7 | BioNTech SE | 27.71 Bn | 9.32 Bn | 668.28 Mn | -18.39 Bn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -1.16 Bn |
| 9 | Royalty Pharma | 27.35 Bn | 26.51 Bn | - | 2.12 Bn |
| 10 | Genelux | 119.65 Mn | 119.65 Mn | - | -21.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -9.27 Mn |
| Dec 31, 2025 | -12.22 Mn |
| Sep 30, 2025 | -20.90 Mn |
| Jun 30, 2025 | -47.65 Mn |
| Mar 31, 2025 | -13.80 Mn |
| Dec 31, 2024 | -30.90 Mn |
| Sep 30, 2024 | -62.42 Mn |
| Jun 30, 2024 | -66.23 Mn |
| Mar 31, 2024 | -35.19 Mn |
| Dec 31, 2023 | -21.70 Mn |
| Sep 30, 2023 | -29.87 Mn |
| Dec 31, 2022 | -397,000.00 |